Advertisement

Drug Safety

, Volume 15, Issue 3, pp 219–231 | Cite as

Gingival Enlargement Induced by Drugs

  • Lluís Brunet
  • Jaume Miranda
  • Magí FarréEmail author
  • Leonardo Berini
  • Carles Mendieta
Review Article Pharmacoepidemiology

Summary

Gingival enlargement, an abnormal growth of the periodontal tissue, is mainly associated with dental plaque-related inflammation and drug therapy. Its true incidence in the general population is unknown. Gingival enlargement produces aesthetic changes, pain, gingival bleeding and periodontal disorders.

Although gingival overgrowth has been traditionally recognised as an adverse effect of phenytoin therapy, it has recently been reported in association with the use of cyclosporin and calcium antagonists. These 3 classes of drugs produce important changes in fibroblast function, which induce an increase in the extracellular matrix of the gingival connective tissue.

In the majority of those patients for whom dosage reduction, or drug discontinuation or substitution is not possible, and for whom prophylactic measures have failed, surgical excision of gingival tissue remains the only treatment of choice.

Keywords

Cyclosporin Adis International Limited Nifedipine Dental Plaque Gingival Fibroblast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carranza FA. Agrandamiento gingival. In: Carranza FA, editor. Periodontologia clínica de Glickman. México: Interamericana McGraw-Hill, 1993: 135–59Google Scholar
  2. 2.
    Hasseil TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Bio Med 1991; 2: 103–37Google Scholar
  3. 3.
    Hirschfeld I. Hypertrophic gingivitis: its clinical aspects. J Am Dent Assoc 1932; 19: 799–801Google Scholar
  4. 4.
    Kimball OP. The treatment of epilepsy with sodium diphenyl-hydantoinate. JAMA 1939; 112: 1244–5Google Scholar
  5. 5.
    Rateitschak-Plüss E, Heftia A, Lotcher R, et al. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983; 10: 237–46PubMedGoogle Scholar
  6. 6.
    Thomason JM, Seymour RA, Soames JV. Severe mucosal hyperplasia of the edentulous maxilla associated with immunosuppressant therapy: a clinical report. J Prosthet Dent 1994; 72: 1–3PubMedGoogle Scholar
  7. 7.
    Ramon Y, Behar S, Kishon Y, et al. Gingival hyperplasia caused by nifedipine: a preliminary report. Int J Cardiol 1984; 5: 195–204PubMedGoogle Scholar
  8. 8.
    Mathis DE, Scheetz AP. Calcium channel antagonists and gingival hyperplasia. Ann Intern Med 1994; 121: 624–5PubMedGoogle Scholar
  9. 9.
    Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992; 63: 453–6PubMedGoogle Scholar
  10. 10.
    Bowman JM, Levy BA, Grubb RV. Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol 1988; 65: 183–5PubMedGoogle Scholar
  11. 11.
    Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 1991; 20: 201–9PubMedGoogle Scholar
  12. 12.
    Fujii A, Matsumoto H, Nakao S, et al. Effect of calcium-channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders. Arch Oral Biol 1994; 39: 99–104PubMedGoogle Scholar
  13. 13.
    Angelopoulos AP. A clinicopathological review: diphenylhydantoin gingival hyperplasia. Incidence, clinical features and histopathology. J Can Dent Assoc 1975; 41: 103–6Google Scholar
  14. 14.
    Angelopoulos AP. A clinicopathological review: diphenylhydantoin gingival hyperplasia. Aetiology, pathogenesis, differential diagnosis and treatment. J Can Dent Assoc 1975; 41: 275–83Google Scholar
  15. 15.
    Hasseil TM, White GG, Jewson LG, et al. Valproic acid: a new antiepileptic drug with potential side effects of dental concern. J Am Dent Assoc 1979; 99: 983–7Google Scholar
  16. 16.
    Wysocki GP, Gretzinger HA, Laupacis A, et al. Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol 1983; 55: 274–8PubMedGoogle Scholar
  17. 17.
    Delliliers GL, Santoro F, Polli N, et al. Light and electron microscopic study of cyclosporin A-induced gingival hyperplasia. J Periodontol 1986; 57: 771–5Google Scholar
  18. 18.
    Rostock MH, Fry HR, Turner JE. Severe gingival overgrowth associated with cyclosporin therapy. J Periodontol 1986; 57: 294–9PubMedGoogle Scholar
  19. 19.
    Hassell T. Evidence that cyclosporin, phenytoin and dihydropiridines elicit overgrowth by different mechanism [abstract 447]. J Dent Res 1990; 69: 164Google Scholar
  20. 20.
    Peñarrocha-Diago M, Bagan-Sebastian JV, Vera-Sempere F. Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. J Periodontol 1990; 61: 571–4PubMedGoogle Scholar
  21. 21.
    Mariani G, Calastrini C, Carinci F, et al. Ultrastructural features of cyclosporin A-induced gingival hyperplasia. J Periodontol 1993; 64: 1092–7PubMedGoogle Scholar
  22. 22.
    Zebrowski EJ, Pylypas SP, Odium O, et al. Comparative metabolism of 3H-glucosamine by fibroblast populations exposed to cyclosporin. J Periodontol 1994; 65: 565–7PubMedGoogle Scholar
  23. 23.
    Tyldesley WR, Rotter E. Gingival hyperplasia induced by ciclosporin-A. Br Dent J 1984; 157: 305–9PubMedGoogle Scholar
  24. 24.
    Zebrowski E, Singer D, Brunka J. Cycloporine-A, nifedipine and phenytoin: comparative effects on gingival fibroblast metabolism. J Dent Res 1986; 65: 331–5Google Scholar
  25. 25.
    Van der Wall E, Tuinzing D, Hiss J. Gingival hyperplasia: a possible side effect of nifedipine. Ned Tijdschn Geneeskd 1984; 128: 1954–5Google Scholar
  26. 26.
    Panuska HJ, Gorlin RJ, Bearman JE, et al. The effect of anticonvulsant drugs upon the gingiva: a series of analyses of 1048 patients. J Periodontol 1960; 31: 336–44Google Scholar
  27. 27.
    Syrjanen S, Syrjanen K. Hyperplastic gingivitis in a child receiving sodium valproate treatment. Proc Finn Dent Soc 1979; 75: 95–8PubMedGoogle Scholar
  28. 28.
    Ciancio SG. Anticonvulsants. In: Holroyd SV, editor. Clinical pharmacology in dental practice. St Louis: Mosby, 1978; 116–20Google Scholar
  29. 29.
    Greenberg MS. Neuromuscular diseases. In: Lynch MA, editor. Burket’s oral medicine. Philadelphia: JB Lippincott Co., 1977: 500–1Google Scholar
  30. 30.
    Hassell TM. Epilepsy and the oral manifestations of phenytoin therapy. New York: Karger, 1981Google Scholar
  31. 31.
    Leppik IE. Antiepileptic medications. Comp Cont Ed Dent 1990; 14: 490–6Google Scholar
  32. 32.
    Kapur RN, Girgis S, Little TM, et al. Diphenylhydantoin-induced gingival hypertrophy: its relationship to dose and serum level. Dev Med Child Neurol 1973; 15: 483–7PubMedGoogle Scholar
  33. 33.
    Addy V, McElnay JC, Eyre DG, et al. Risk factors in phenytoin-induced gingival hyperplasia. J Periodontol 1983; 54: 373–7PubMedGoogle Scholar
  34. 34.
    Perlík F, Kolínová M, Zvárová J, et al. Phenytoin as a risk factor in gingival hyperplasia. Ther Drug Monit 1995; 17: 445–8PubMedGoogle Scholar
  35. 35.
    Hassell TM, O’Donnell J, Pearlman J, et al. Phenytoin-induced gingival overgrowth in institutionalized epileptics. J Clin Periodontol 1984; 11: 242–53PubMedGoogle Scholar
  36. 36.
    Dahllöf G, Modéer T, Reinholt FP, et al. Proteoglycans and glycosaminoglycans in phenytoin-induced gingival overgrowth. J Periodont Res 1986; 21: 13–21PubMedGoogle Scholar
  37. 37.
    Chee WW, Jansen CE. Phenytoin hyperplasia occurring in relation to titanium implants: a clinical report. Int J Oral Maxillofac Implants 1994; 9: 107–9PubMedGoogle Scholar
  38. 38.
    Harris TH, Ewalt JR. Complications following the use of sodium diphenylhydantoinate (Dilantin) therapy. J Oklahoma State Med Assoc 1942; 35: 365–70Google Scholar
  39. 39.
    Livingston S, Livingston H. Diphenylhydantoin gingival hyperplasia. Am J Dis Child 1969; 117: 265–70PubMedGoogle Scholar
  40. 40.
    Lennox WG. The drug therapy of epilepsy. JAMA 1940; 114: 1347–54Google Scholar
  41. 41.
    Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972; 34: 898–906PubMedGoogle Scholar
  42. 42.
    Delasnerie-Lauprêtre N, Turpin JC. Evaluation of the prevalence of side effects of phenobarbital in the Champagne-Ardenne region (France). Pathol Biol 1991; 39: 780–4PubMedGoogle Scholar
  43. 43.
    Russo L. Valproate-induced stomatitis. Neurology 1981; 31: 329–31PubMedGoogle Scholar
  44. 44.
    Seymour RA, Smith DG, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985; 12: 413–9PubMedGoogle Scholar
  45. 45.
    Lundström A, Eeg-Olofsson O, Hamp SE. Effects of anti-epileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents. J Clin Periodontol 1982; 9: 482–8PubMedGoogle Scholar
  46. 46.
    Britton S, Palacios R. Cyclosporin A: usefulness, risks and mechanism of action. Immunologic Rev 1982; 65: 5–21Google Scholar
  47. 47.
    Adams D, Davies G. Gingival hyperplasia induced by cyclosporin A. Br Dent J 1984; 157: 89–90PubMedGoogle Scholar
  48. 48.
    Bennett J, Christian J. Cyclosporin-induced gingival hyperplasia: case report and literature review. J Am Dent Assoc 1985; 111: 272–3PubMedGoogle Scholar
  49. 49.
    Coley C, Jarvis K, Hasseil T. Effect of cyclosporin-A on human gingival fibroblasts in vitro [abstract 1658]. J Dent Res 1986; 65: 353Google Scholar
  50. 50.
    Seymour RA, Heasman PA. Adverse drug reactions and the periodontal tissues. In: Seymour RA, Heasman PA, Macgregor IDM, editors. Drugs, diseases, and the periodontium. London: Oxford University Press, 1992: 77–91Google Scholar
  51. 51.
    Daley TD, Wysocki GP, May C. Clinical and pharmacological correlations in cyclosporin-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986; 62: 417–21PubMedGoogle Scholar
  52. 52.
    McGaw T, Lam S, Coates J. Cyclosporin-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores, and cyclosporin levels in serum and saliva. Oral Surg Oral Med Oral Pathol 1987; 64: 293–7PubMedGoogle Scholar
  53. 53.
    Camargo PMD. Cyclosporin- and nifedipine-induced gingival enlargement: an overview. J West Soc Periodontal 1989; 37: 57–64Google Scholar
  54. 54.
    Somacarrera ML, Hernández G, Acero J, et al. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol 1994; 65: 671–5PubMedGoogle Scholar
  55. 55.
    Hefti AF, Eshenaur AE, Hasseil TM, et al. Gingival overgrowth in cyclosporin A treated multiple sclerosis patients. J Periodontol 1994; 65: 744–9PubMedGoogle Scholar
  56. 56.
    Wondimu B, Sandberg J, Modéer T. Gingival overgrowth in renal transplant patients administered cyclosporin A in mixture or in capsule form. A longitudinal study. Clin Transplantation 1996; 10: 71–6Google Scholar
  57. 57.
    Friskopp J, Klintmalm G. Gingival enlargement: a comparison between cyclosporin and azathioprine-treated renal allograft recipients. Swed Dent J 1986; 10: 85–92PubMedGoogle Scholar
  58. 58.
    Friskopp J, Engström P, Sundqvist K. Characterisation of mononuclear cells in cyclosporin-A induced gingival enlargement. Scand J Dent Res 1986; 94: 443–7PubMedGoogle Scholar
  59. 59.
    Slavin J, Taylor J. Cyclosporin, nifedipine, and gingival hyperplasia [letter]. Lancet 1987; II: 739Google Scholar
  60. 60.
    Pernu HE, Pernu LM, Knuuttila ML. Effect of periodontal treatment on gingival overgrowth among cyclosporin A-treated renal transplant recipients. J Periodontol 1993; 64: 1098–100PubMedGoogle Scholar
  61. 61.
    Bokenkamp A, Bohnhorst B, Beier C, et al. Nifedipine aggravates cyclosporin A-induced gingival hyperplasia. Pediatr Nephrol 1994; 8: 181–5PubMedGoogle Scholar
  62. 62.
    Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993; 20: 37–40PubMedGoogle Scholar
  63. 63.
    King GN, Fullinfaw R, Higgins TJ, et al. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993; 20: 286–93PubMedGoogle Scholar
  64. 64.
    Laupacis A, Canadian Transplant Study Group. Complications of Cy-A therapy compared to azathioprine. Transplant Proc 1983; 15: 2748–53Google Scholar
  65. 65.
    Allman SD, McWhorter AG, Seale NS. Evaluation of cyclosporin-induced gingival overgrowth in the pediatric transplant patient. Pediatr Dent 1994; 16: 36–40PubMedGoogle Scholar
  66. 66.
    Neumayer HH, Budde K, Färber L, et al. Conversion to microemulsion cyclosporin in stable renal transplant patients: results after one year. Clin Nephrol 1996; 45: 326–31PubMedGoogle Scholar
  67. 67.
    Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporin in the treatment of psoriasis. Arch Dermatol 1996; 132: 623–9PubMedGoogle Scholar
  68. 68.
    Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporin A. Br Dent J 1984; 157: 305–9PubMedGoogle Scholar
  69. 69.
    Seymour RA, Heasman PA. Drugs and periodontium. J Clin Periodontol 1988; 15: 1–16PubMedGoogle Scholar
  70. 70.
    O’Mesa F, Aneiros J, et al. Gingival overgrowth induced by nifedipine and cyclosporin A. Clinical and morphometric study with image analysis. J Clin Periodontol 1995; 22: 591–7Google Scholar
  71. 71.
    Beveridge T. Cyclosporin A: clinical results. Transplant Proc 1983; 15: 433–7Google Scholar
  72. 72.
    Thomason JM, Seymour RA, Soames JV. Severe mucosal hyperplasia of the edentulous maxilla associated with immunosuppressant therapy: a clinical report. J Prosthet Dent 1994; 72: 1–3PubMedGoogle Scholar
  73. 73.
    Lavarenne J. Side-effects of calcium inhibitors. Therapie 1989; 44: 197–200PubMedGoogle Scholar
  74. 74.
    Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994; 120: 663–4PubMedGoogle Scholar
  75. 75.
    Physician’s Desk Reference. 45th ed. Oradell (NJ): Medical Economics Co. Inc., 1991: 2055–8Google Scholar
  76. 76.
    Facts and Comparisons. St Louis: Facts and Comparisons Inc., 1991: 149b–50bGoogle Scholar
  77. 77.
    Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia: a histochemical and ultrastructural study. J Periodontol 1985; 56: 211–5PubMedGoogle Scholar
  78. 78.
    Lederman D, Lumerman H, Reuben S, et al. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral Surg Oral Med Oral Pathol 1984; 57: 620–2PubMedGoogle Scholar
  79. 79.
    Ramon Y, Behar S, Kishon Y, et al. Gingival hyperplasia caused by nifedipine: a preliminary report. Int J Cardiol 1984; 5: 195–204PubMedGoogle Scholar
  80. 80.
    Shaftic AA, Widdup LL, Abate MA, et al. Nifedipine-induced gingival hyperplasia. Drug Intell Clin Pharm 1986; 20: 602–13PubMedGoogle Scholar
  81. 81.
    Meirnyska A, Abrahamnyska M, Gotsman M. Nifedipine-induced gingival hyperplasia: case reports and literature review. Isr J Med Sci 1989; 25: 453–5Google Scholar
  82. 82.
    Bencini PL, Crosti C, Sala F, et al. Iperplasia gengivale da nifedipina. Giorn It Derm Vener 1986; 121: 29–31Google Scholar
  83. 83.
    Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine: histopathologic findings. J Periodontol 1987; 58: 639–42PubMedGoogle Scholar
  84. 84.
    Doria G, Cangemi F, Gulizia M, et al. Su tre casi di iperplasia gengivale in corso di terapia con nifedipina. Minerva Cardioangiol 1990; 38: 97–100PubMedGoogle Scholar
  85. 85.
    Gonzalez-Jaranay M, Mesa F. Nifedipine induced gingival hyperplasia. Rev Eur Odontoestomatol 1991; 3: 127–30PubMedGoogle Scholar
  86. 86.
    Garcia Bernai G, Collado A, Ceron A. Hiperplasia gingival como reacción adversa a nifedipina [letter]. Atencion Primaria 1991; 8: 265Google Scholar
  87. 87.
    Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991; 170: 376–9PubMedGoogle Scholar
  88. 88.
    Bullon P, Machuca P, Martínez-Sahuquillo A, et al. Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 1994; 21: 256–9PubMedGoogle Scholar
  89. 89.
    Nery EB, Edson RG, Lee KK, et al. Prevalence of nifedipine induced gingival hyperplasia. J Periodontol 1995; 66: 572–8PubMedGoogle Scholar
  90. 90.
    Fattore L, Stablein M, Bredfeldt G, et al. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist 1991; 11: 107–9PubMedGoogle Scholar
  91. 91.
    Iwakura M, Shibuya Y, Obara Y, et al. Prevalence of gingival hyperplasia in the patients associated with nifedipine (antihypertensive drug) therapy. J Dent Health 1987; 37: 574–5Google Scholar
  92. 92.
    Katsumi Y, Takahara M, Watanabe Y, et al. Statistical study of incidence of gingival hyperplasia induced by hypotensive drugs. (Ca channel blockers). J Jpn Stomatol Soc 1991; 40: 169–78Google Scholar
  93. 93.
    Barclay S, Thomason JM, Idle JR, et al. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992; 19: 311–4PubMedGoogle Scholar
  94. 94.
    Steele R, Schuna A, Schreiber R. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994; 120: 663–4PubMedGoogle Scholar
  95. 95.
    Brown RS, Sein P, Corio R, et al. Nitrendipine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1990; 70: 593–6PubMedGoogle Scholar
  96. 96.
    Nagano S, Ogawa T, Fukuyama S, et al. Influence of nicardipine hydrochlorhide on hypotensive effect and insulin secretion in a patient of hypertensive diabetic mellitus. Jpn Pharmacol Ther 1985; 19: 5309–13Google Scholar
  97. 97.
    Lombardi T, Fiore-Donno, Belser U, et al. Felodipine-induced gingival hyperplasia: a clinical and histologic study. J Oral Pathol Med 1991; 20: 89–92PubMedGoogle Scholar
  98. 98.
    Seymour RA, Ellis JS, Thomason JM, et al. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994; 21: 281–3PubMedGoogle Scholar
  99. 99.
    Juncadella E, Fandos JM, Alba J, et al. Hiperplasia gingival inducida por amlodipino. Med Clin (Barc) 1994; 103: 358–359Google Scholar
  100. 100.
    Heijl L, Sundin Y. Nitrendipine-induced gingival overgrowth in dogs. J Periodontol 1988; 60: 104–12Google Scholar
  101. 101.
    Hashigichi J, Hisatomi M, Watari N, et al. Single and repeated dose toxicity studies on lacidipine in beagle dogs. Jpn Pharmacol Ther 1994; 22: 343–75Google Scholar
  102. 102.
    Wanner T, Nyska A, Nyska M, et al. Gingival hyperplasia in dogs induced by oxodipine, a calcium channel blocking agent. Toxicol Pathol 1988; 16: 327–32Google Scholar
  103. 103.
    Cucchi G, Giustianini S, Robustelli F. Gingival hyperplasia caused by verapamil. Ital J Cardiol 1985; 15: 556–7Google Scholar
  104. 104.
    Smith M, Glenert U. Gingivhyperplasi forarsaget af behandling med verapamil. Tandlaegebladet 1987; 91: 849–50Google Scholar
  105. 105.
    Pernu HE, Oikarinen K, Hietanen J, et al. Verapamil-induced gingival overgrowth: a clinical, histologic, and biochemical approach. J Oral Pathol Med 1989; 18: 422–5PubMedGoogle Scholar
  106. 106.
    Colvard MD, Bishop J, Weissman D, et al. Cardizem-induced gingival hyperplasia. Periodontal Case Rep 1986; 8: 67–8PubMedGoogle Scholar
  107. 107.
    Giustiniani S, Della Cuna FR, Marien M. Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 1987; 15: 247–9PubMedGoogle Scholar
  108. 108.
    Bowman J, Levy B, Grubb R. Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol 1988; 65: 183–5PubMedGoogle Scholar
  109. 109.
    Lynn BD. ‘The pill’ as an etiologic agent in hypertrophic gingivitis. Oral Surg Oral Med Oral Pathol 1967; 24: 333–4PubMedGoogle Scholar
  110. 110.
    Kaufman AY. An oral contraceptive as an aetiologic factor in producing hyperplastic gingivitis and a neoplasm of the pregnancy tumour type. Oral Surg Oral Med Oral Pathol 1969; 28: 666–70PubMedGoogle Scholar
  111. 111.
    Sperber GH. Oral contraceptive hypertrophic gingivitis. J Dent Assoc S Afr 1969; 24: 37–40PubMedGoogle Scholar
  112. 112.
    Chevallier ME. Mouth manifestations and oral contraceptives. Rev Odontoestomatol Midi Fr 1970; 28: 96–103Google Scholar
  113. 113.
    El-Ashiry GM, El-Kafrawy AH, Nasr MF, et al. Comparative study of the influence of pregnancy and oral contraceptives on the gingivae. Oral Surg Oral Med Oral Pathol 1970; 30: 472–5PubMedGoogle Scholar
  114. 114.
    Das AK, Bhomick S, Dutta A. Oral contraceptives and periodontal disease. J Indian Dent Assoc 1971; 43: 155–8PubMedGoogle Scholar
  115. 115.
    Hall WB. Dilantin hyperplasia. J Periodontal Res 1965; 4: 36–7Google Scholar
  116. 116.
    Ciancio SD. Gingival hyperplasia and diphenylhydantoin: a longitudinal study [abstract 65]. J Dent Res 1970; 49Google Scholar
  117. 117.
    Lopez A, Hernández G, Gold S. Control of gingival enlargement induced by nifedipine [abstract 2037]. J Dent Res 1994; 73: 356Google Scholar
  118. 118.
    Modéer T, Dahllöf G. Development of phenytoin-induced gingival overgrowth in non-institutionalized epileptic children subjected to different plaque control programs. Acta Odontol Scand 1987; 45: 81–5PubMedGoogle Scholar
  119. 119.
    Seymour RA, Ellis JS, Thomason JM. Drug-induced gingival overgrowth and its management. J R Coll Surg Edinb 1993; 38: 328–32PubMedGoogle Scholar
  120. 120.
    O’Neil TCA, Figures KH. The effects of Chlorhexidine and mechanical methods of plaque control on the recurrence of gingival hyperplasia in young patients taking phenytoin. Br Dent J 1982; 16: 130–3Google Scholar
  121. 121.
    Shibly O, Ciancio S, Anderson T, et al. The role of 0.12% clohexidine gluconate in drug-induced hyperplasia [abstract 2034]. J Dent Res 1994; 73: 356Google Scholar
  122. 122.
    George R, Pack ARC. Inhibition of mitogen-induced lymphoblastic transformation by folate [abstract 40]. J Dent Res 1983; 62: 404Google Scholar
  123. 123.
    Hermos JA, Adams WH, Liu YK. Mucosa of the small intestine in folate deficient alcoholics. Ann Intern Med 1972; 76: 957–65PubMedGoogle Scholar
  124. 124.
    Whitehead N, Reyner F, Lindenbaum J. Megaloblastic changes in the cervical epithelium: association with oral contraceptive therapy and reversal with folic acid. JAMA 1973; 226: 1421–4PubMedGoogle Scholar
  125. 125.
    Olesen OV, Jensen ON. The influence of folic acid on phenytoin DPH (metabolism and the 24 hour fluctuation in urinary output of 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH). Acta Pharmacol Toxicol 1980; 7: 402–13Google Scholar
  126. 126.
    Girwood RH. Folic acid, its analogues and antagonists. In: Sobotka H, Steward CP, editors. Advances in clinical chemistry. New York: Academic Press, 1960: 235–53Google Scholar
  127. 127.
    Klipstein FA. Subnormal serum folate and a macrocytosis associated with anticonvulsant drug therapy. Blood 1964; 23: 68–84PubMedGoogle Scholar
  128. 128.
    Brown RS, Si Stanislao PT, Beaver WT, et al. The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia: a double-blind, randomized, placebo-controlled, parallel study. Oral Surg Oral Med Oral Pathol 1991; 71: 655–68Google Scholar
  129. 129.
    Drew HJ, Vogel RY, Molofsky W, et al. Effect of folate on phenytoin hyperplasia. J Clin Periodontol 1987; 14: 350–6PubMedGoogle Scholar
  130. 130.
    Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole [letter]. Lancet 1994; 343: 986PubMedGoogle Scholar
  131. 131.
    Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporin-associated gingival hyperplasia with azithromycin therapy. New Eng J Med 1995; 332: 753–4PubMedGoogle Scholar
  132. 132.
    Valsecchi R, Cinelli T. Gingival hyperplasia induced by erythromycin [letter]. Acta Derm Venereol 1992; 72: 157PubMedGoogle Scholar
  133. 133.
    Staple PH. Some tissue reactions associated with 5, 5-diphenyl-hydantoin (‘dilantin’) sodium therapy [letter]. Br Dent J 1953; 95: 289Google Scholar
  134. 134.
    Van der Kwast W. Speculations regarding the nature of gingival hyperplasia due to diphenylhydantoin-sodium. Acta Med Scand 1956; 153: 399–405Google Scholar
  135. 135.
    Walker CR, Tomich CE, Hutton CE. Treatment of phenytoin-induced gingival hyperplasia by electrosurgery. J Oral Surg 1980; 38: 306–11PubMedGoogle Scholar
  136. 136.
    Daley TD, Wysocki GP. Cyclosporin therapy. Its significance to the periodontist. J Periodontol 1984; 55: 708–12PubMedGoogle Scholar
  137. 137.
    Pernu HE, Oikarinen K, Hietanen J, et al. Verapamil-induced gingival overgrowth: a clinical, histologic and biochemical approach. J Oral Pathol Med 1989; 18: 422–5PubMedGoogle Scholar
  138. 138.
    Nishikawa S, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991; 62: 30–5PubMedGoogle Scholar
  139. 139.
    Dahllöf G, Axio E, Modéer T. Regression of phenytoin-induced gingival overgrowth after withdrawal of medication. Swed Dent J 1991; 15: 139–43PubMedGoogle Scholar
  140. 140.
    Piattelli A, Petrelli I, Fanci P. Regression following reduction of daily drug dosage in cyclosporin A-induced gingival overgrowth in bone marrow transplant recipients. Acta Stomatol Belg 1993; 90: 171–6PubMedGoogle Scholar
  141. 141.
    Livingston S, Livingston HL. Diphenylhydantoin gingival hyperplasia. Am J Dis Child 1969; 117: 265–70PubMedGoogle Scholar
  142. 142.
    Cohen ES. Gingivectomy and gingivoplasty. In: Cohen ES, editor. Atlas of periodontal surgery. Philadelphia: Lea & Febiger, 1988: 29–40Google Scholar
  143. 143.
    Genco J, Henry M, Walter D. Cirugia periodontal. In: Genco J, Henry M, Walter D, editors. Periodoncia. Mexico: Inter-americana McGraw Hill, 1993: 597–601Google Scholar
  144. 144.
    Löe H. Chemical gingivectomy: effect of potassium hydroxide on periodontal tissues. Acta Odontol Scand 1961; 19: 517–37PubMedGoogle Scholar
  145. 145.
    Pick RM, Pecaro BC, Silberman CJ. The laser gingivectomy: the use of the CO2 laser for the removal of phenytoin hyperplasia. J Periodontol 1985; 56: 492–6PubMedGoogle Scholar
  146. 146.
    Barak S, Kaplan I. The CO2 laser in the excision of gingival hyperplasia caused by nifedipine. J Clin Periodontol 1988; 15: 633–5PubMedGoogle Scholar
  147. 147.
    Hylton RP. Use of CO2 laser for gingivectomy in a patient with Sturge-Weber disease complicated by dilantin hyperplasia. J Oral Maxillofac Surg 1986; 44: 646–8PubMedGoogle Scholar
  148. 148.
    Abt E, Wigdor H, Lobraico R, et al. Removal of benign intraoral masses using the CO2 laser. J Am Dent Assoc 1987; 115: 729–31PubMedGoogle Scholar
  149. 149.
    Kaplan I, Raif J. The Sharplan carbon dioxide laser in clinical surgery: 7 years experience. In: Kaplan I, Raif J, editors. The biomedical laser. New York: Springer-Verlag, 1981: 90–102Google Scholar
  150. 150.
    Kaplan I, Giller S. CO2 laser surgery. 1st ed. Berlin: Springer-Verlag, 1984: 13–203Google Scholar
  151. 151.
    Roed-Petersen B. The potential use of CO2-laser gingivectomy for phenytoin-induced gingival hyperplasia in mentally retarded patients. J Clin Periodontol 1993; 20: 729–31PubMedGoogle Scholar
  152. 152.
    Carruth JAS. Resection of the tongue with the carbon dioxide laser. J Laryngol Otol 1982; 96: 529–43PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Lluís Brunet
    • 1
  • Jaume Miranda
    • 1
  • Magí Farré
    • 2
    Email author
  • Leonardo Berini
    • 3
  • Carles Mendieta
    • 1
  1. 1.Unit of Periodontics, Facultat d’OdontologiaUniversitat de BarcelonaBarcelonaSpain
  2. 2.Department of Pharmacology, Institut Municipal d’Investigació Mèdica (IMIM)Universitat Autònoma de BarcelonaBarcelonaSpain
  3. 3.Unit of Oral Surgery, Facultat d’OdontologiaUniversitat de BarcelonaBarcelonaSpain

Personalised recommendations